Cathie Wood’s ARK Invest made notable trades on Friday, March 14, 2025, adjusting its positions in several companies. The firm’s ETFs engaged in both buying and selling, reflecting a strategic shift in its holdings.
Major Sale: UIPATH Inc.
The most significant transaction of the day was ARK’s decision to sell shares of UIPATH Inc. The firm offloaded a total of 1,250,919 shares through its ARKK and ARKW ETFs, generating around $12.47 million in cash. This sale follows a pattern, as ARK has been consistently reducing its investment in UIPATH over the past week.
GITLAB Inc. Sees Increased Investment
While ARK trimmed its UIPATH stake, it increased its holdings in GITLAB Inc. The firm purchased 104,153 shares through ARKK and ARKW ETFs, investing more than $5.2 million in the company. This move follows another GITLAB purchase just a day earlier, indicating ARK’s confidence in the stock.
Continued Accumulation of IBOTTA Shares
ARK also expanded its position in IBOTTA Inc., buying 79,201 shares through ARKW and ARKF ETFs. The total purchase value stood at $3.17 million. This marks another step in ARK’s ongoing accumulation of IBOTTA shares over multiple trading sessions.
Investment in Gene-Editing Company INTELLIA
Another company that gained ARK’s attention was INTELLIA Therapeutics Inc., a player in the gene-editing industry. The firm purchased 67,520 shares through ARKK and ARKG ETFs, investing approximately $622,534 in the company.
Other Key Trades: Roblox, CareDx, and More
On the selling side, ARK divested 47,153 shares of CareDx Inc. through its ARKG ETF, cashing in around $831,778. Additionally, it sold 46,026 shares of Prime Medicine Inc. via ARKK ETF for approximately $79,164.
Another notable sale involved Roblox Corp., with ARK selling 38,757 shares through ARKW and ARKF ETFs, bringing in nearly $2.16 million. The firm also reduced its stake in Repare Therapeutics Inc., selling 53,449 shares through ARKG ETF for around $59,862.
ARK’s Evolving Strategy
These trades highlight ARK’s evolving investment approach, adjusting its portfolio based on market trends and long-term vision. As investors closely follow Cathie Wood’s moves, the latest transactions provide insight into the firm’s strategic thinking and where it sees future potential.
